111 related articles for article (PubMed ID: 29783409)
1. Innovative tests for patient-tailored treatments: demonstrating value in the age of personalized medicine.
Housman L
Per Med; 2011 Mar; 8(2):183-189. PubMed ID: 29783409
[TBL] [Abstract][Full Text] [Related]
2. [Clinical and health economic challenges of personalized medicine].
Brüggenjürgen B; Kornbluth L; Ferrara JV; Willich SN
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):710-4. PubMed ID: 22526860
[TBL] [Abstract][Full Text] [Related]
3. Will personalized medicine help in 'transforming' the business of healthcare?
Lester DS
Per Med; 2009 Sep; 6(5):555-565. PubMed ID: 29783307
[TBL] [Abstract][Full Text] [Related]
4. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
[TBL] [Abstract][Full Text] [Related]
5. Consensus document on European brain research.
Olesen J; Baker MG; Freund T; di Luca M; Mendlewicz J; Ragan I; Westphal M
J Neurol Neurosurg Psychiatry; 2006 Aug; 77 Suppl 1(Suppl 1):i1-49. PubMed ID: 16845120
[TBL] [Abstract][Full Text] [Related]
6. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.
O'Donnell JC
Value Health; 2013; 16(6 Suppl):S1-3. PubMed ID: 24034305
[TBL] [Abstract][Full Text] [Related]
7. Biopharmaceutical industry perspectives on the business prospects for personalized medicine.
Milne CP; Zuckerman R
Per Med; 2011 Sep; 8(5):541-550. PubMed ID: 29793252
[TBL] [Abstract][Full Text] [Related]
8. Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research.
Siebert U; Jahn B; Rochau U; Schnell-Inderst P; Kisser A; Hunger T; Sroczynski G; Mühlberger N; Willenbacher W; Schnaiter S; Endel G; Huber L; Gastl G;
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):330-40. PubMed ID: 26354133
[TBL] [Abstract][Full Text] [Related]
9. Beware the Medical-Industrial Complex.
Stevens CW; Glatstein E
Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population.
De Andrés F; Terán S; Hernández F; Terán E; LLerena A
OMICS; 2016 Dec; 20(12):699-710. PubMed ID: 27849442
[TBL] [Abstract][Full Text] [Related]
12. A coalition to drive personalized medicine forward.
Munroe JB
Per Med; 2004 Dec; 1(1):9-13. PubMed ID: 29793218
[TBL] [Abstract][Full Text] [Related]
13. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
14. Driving forces behind the past and future emergence of personalized medicine.
Steffen JA; Steffen JS
J Pers Med; 2013 Jan; 3(1):14-22. PubMed ID: 25562408
[TBL] [Abstract][Full Text] [Related]
15. [Early achievements of the Danish pharmaceutical industry-7].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2014; (42):31-62. PubMed ID: 25816561
[TBL] [Abstract][Full Text] [Related]
16. Reimbursement and coverage challenges associated with bringing emerging molecular diagnostics into the personalized medicine paradigm.
Ridge JR
Per Med; 2006 Aug; 3(3):345-348. PubMed ID: 29788649
[TBL] [Abstract][Full Text] [Related]
17. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
18. Impact of molecular medicine on healthcare markets and strategies for success.
Miller PS; Batchelder KF
Per Med; 2009 Sep; 6(5):529-542. PubMed ID: 29783311
[TBL] [Abstract][Full Text] [Related]
19. From blockbuster medicine to personalized medicine.
Jørgensen JT
Per Med; 2008 Jan; 5(1):55-63. PubMed ID: 29783394
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
